Literature DB >> 15542644

Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein.

Ana P Goncalvez1, Robert H Purcell, Ching-Juh Lai.   

Abstract

The epitope determinants of chimpanzee Fab antibody 1A5, which have been shown to be broadly reactive to flaviviruses and efficient for cross-neutralization of dengue virus type 1 and type 2 (DENV-1 and DENV-2), were studied by analysis of DENV-2 antigenic variants. Sequence analysis showed that one antigenic variant contained a Gly-to-Val substitution at position 106 within the flavivirus-conserved fusion peptide loop of the envelope protein (E), and another variant contained a His-to-Gln substitution at position 317 in E. Substitution of Gly(106)Val in DENV-2 E reduced the binding affinity of Fab 1A5 by approximately 80-fold, whereas substitution of His(317)Gln had little or no effect on antibody binding compared to the parental virus. Treatment of DENV-2 with beta-mercaptoethanol abolished binding of Fab 1A5, indicating that disulfide bridges were required for the structural integrity of the Fab 1A5 epitope. Binding of Fab 1A5 to DENV-2 was competed by an oligopeptide containing the fusion peptide sequence as shown by competition enzyme-linked immunosorbent assay. Both DENV-2 antigenic variants were shown to be attenuated, or at least similar to the parental virus, when evaluated for growth in cultured cells or for neurovirulence in mice. Fab 1A5 inhibited low pH-induced membrane fusion of mosquito C6/36 cells infected with DENV-1 or DENV-2, as detected by reduced syncytium formation. Both substitutions in DENV-2 E lowered the pH threshold for membrane fusion, as measured in a fusion-from-within assay. In the three-dimensional structure of E, Gly(106) in domain II and His(317) in domain III of the opposite E monomer were spatially close. From the locations of these amino acids, Fab 1A5 appears to recognize a novel epitope that has not been mapped before with a flavivirus monoclonal antibody.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15542644      PMCID: PMC525008          DOI: 10.1128/JVI.78.23.12919-12928.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  Binding of an antibody mimetic of the human low density lipoprotein receptor to apolipoprotein E is governed through electrostatic forces. Studies using site-directed mutagenesis and molecular modeling.

Authors:  R Raffaï; K H Weisgraber; R MacKenzie; B Rupp; E Rassart; T Hirama; T L Innerarity; R Milne
Journal:  J Biol Chem       Date:  2000-03-10       Impact factor: 5.157

2.  Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site.

Authors:  B Blondel; R Crainic; O Fichot; G Dufraisse; A Candrea; D Diamond; M Girard; F Horaud
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

3.  Oligomeric rearrangement of tick-borne encephalitis virus envelope proteins induced by an acidic pH.

Authors:  S L Allison; J Schalich; K Stiasny; C W Mandl; C Kunz; F X Heinz
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

4.  Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).

Authors:  J Arroyo; F Guirakhoo; S Fenner; Z X Zhang; T P Monath; T J Chambers
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

5.  Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States.

Authors:  R S Lanciotti; J T Roehrig; V Deubel; J Smith; M Parker; K Steele; B Crise; K E Volpe; M B Crabtree; J H Scherret; R A Hall; J S MacKenzie; C B Cropp; B Panigrahy; E Ostlund; B Schmitt; M Malkinson; C Banet; J Weissman; N Komar; H M Savage; W Stone; T McNamara; D J Gubler
Journal:  Science       Date:  1999-12-17       Impact factor: 47.728

6.  Identification of chimpanzee Fab fragments by repertoire cloning and production of a full-length humanized immunoglobulin G1 antibody that is highly efficient for neutralization of dengue type 4 virus.

Authors:  Ruhe Men; Tetsu Yamashiro; Ana P Goncalvez; Claire Wernly; Darren J Schofield; Suzanne U Emerson; Robert H Purcell; Ching-Juh Lai
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

7.  Antigenicity of the N8 influenza A virus neuraminidase: existence of an epitope at the subunit interface of the neuraminidase.

Authors:  T Saito; G Taylor; W G Laver; Y Kawaoka; R G Webster
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

8.  Sequence analysis of the membrane protein V3 of the flavivirus West Nile virus and of its gene.

Authors:  G Wengler; E Castle; U Leidner; T Nowak; G Wengler
Journal:  Virology       Date:  1985-12       Impact factor: 3.616

Review 9.  Dengue: the risk to developed and developing countries.

Authors:  T P Monath
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

10.  Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.

Authors:  J P Moore; Y Cao; L Qing; Q J Sattentau; J Pyati; R Koduri; J Robinson; C F Barbas; D R Burton; D D Ho
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

View more
  42 in total

1.  Crystal structure of west nile virus envelope glycoprotein reveals viral surface epitopes.

Authors:  Ryuta Kanai; Kalipada Kar; Karen Anthony; L Hannah Gould; Michel Ledizet; Erol Fikrig; Wayne A Marasco; Raymond A Koski; Yorgo Modis
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

2.  Impact of quaternary organization on the antigenic structure of the tick-borne encephalitis virus envelope glycoprotein E.

Authors:  Stefan Kiermayr; Karin Stiasny; Franz X Heinz
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

Review 3.  Closing the door on flaviviruses: entry as a target for antiviral drug design.

Authors:  Rushika Perera; Mansoora Khaliq; Richard J Kuhn
Journal:  Antiviral Res       Date:  2008-06-11       Impact factor: 5.970

4.  West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody.

Authors:  Bärbel Kaufmann; Grant E Nybakken; Paul R Chipman; Wei Zhang; Michael S Diamond; Daved H Fremont; Richard J Kuhn; Michael G Rossmann
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-08       Impact factor: 11.205

5.  Induction of epitope-specific neutralizing antibodies against West Nile virus.

Authors:  Theodore Oliphant; Grant E Nybakken; S Kyle Austin; Qing Xu; Jonathan Bramson; Mark Loeb; Mark Throsby; Daved H Fremont; Theodore C Pierson; Michael S Diamond
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

6.  Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype.

Authors:  W W Shanaka I Rodrigo; Olivia K T Block; Christopher Lane; Soila Sukupolvi-Petty; Ana P Goncalvez; Syd Johnson; Michael S Diamond; Ching-Juh Lai; Robert C Rose; Xia Jin; Jacob J Schlesinger
Journal:  Virology       Date:  2009-10-14       Impact factor: 3.616

7.  The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1.

Authors:  Bimmi Shrestha; James D Brien; Soila Sukupolvi-Petty; S Kyle Austin; Melissa A Edeling; Taekyung Kim; Katie M O'Brien; Christopher A Nelson; Syd Johnson; Daved H Fremont; Michael S Diamond
Journal:  PLoS Pathog       Date:  2010-04-01       Impact factor: 6.823

8.  Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop.

Authors:  Joshua M Costin; Elena Zaitseva; Kristen M Kahle; Cindo O Nicholson; Dawne K Rowe; Amanda S Graham; Lindsey E Bazzone; Greg Hogancamp; Marielys Figueroa Sierra; Rachel H Fong; Sung-Tae Yang; Li Lin; James E Robinson; Benjamin J Doranz; Leonid V Chernomordik; Scott F Michael; John S Schieffelin; Sharon Isern
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

9.  Monoclonal antibodies that bind to common epitopes on the dengue virus type 2 nonstructural-1 and envelope glycoproteins display weak neutralizing activity and differentiated responses to virulent strains: implications for pathogenesis and vaccines.

Authors:  Andrew K I Falconar
Journal:  Clin Vaccine Immunol       Date:  2007-12-26

10.  Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens.

Authors:  Wayne D Crill; Holly R Hughes; Mark J Delorey; Gwong-Jen J Chang
Journal:  PLoS One       Date:  2009-04-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.